May 22, 2023

Willkie advised eureKING, the first European special purpose acquisition company in healthcare dedicated to bioproduction, in connection with its proposed acquisition of Skyepharma, a key player in drug development and delivery of oral technologies serving the global pharmaceutical, biotech and consumer health industries. 

On May 16, eureKING announced that it submitted an offer to acquire Skyepharma and has been an exclusivity period to pursue the transaction. The proposed combination would represent a major step in eureKING’s project to create a new European fully integrated bio-CDMO leader offering a unique solution to biotechs to develop and manufacture their products.

The Willkie team was led by partner Fabrice Veverka and counsel Charles Fillon and included associate Juline Pottiez.